Efficacy of Acetaminophen Alone Versus Combination of Acetaminophen/Ibuprofen After Cesarean Section
NCT ID: NCT06479122
Last Updated: 2025-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
84 participants
INTERVENTIONAL
2024-10-09
2026-08-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Post-cesarean Analgesia: Comparing Effectiveness of Staggered v. Simultaneous Therapies
NCT07102641
RCT (Randomized Controlled Trial) of IV Acetaminophen for Post Cesarean Pain Relief
NCT02046382
Propacetamol to Reduce Post Cesarean Section Uterine Contraction Pain
NCT03878082
Additive Effect of Intravenous Acetaminophen on Postoperative Pain Control
NCT03644147
Efficacy of Acetaminophen-ibuprofen Combination on the Postoperative Pain After Thyroidectomy
NCT05626010
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acetaminophen
Acetaminophen
1g acetaminophen is administered during skin closure (end of operation).
Acetaminophen
1g acetaminophen is administered 6 hours after the first administration.
Acetaminophen/Ibuprofen
Acetaminophen/Ibuprofen
A mixture of 1g acetaminophen and 300 mg ibuprofen (Maxigesic®IV) is administered during skin closure (end of operation)
Acetaminophen/Ibuprofen
A mixture of 1g acetaminophen and 300 mg ibuprofen (Maxigesic®IV) is administered 6 hours after the first administration.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Acetaminophen
1g acetaminophen is administered during skin closure (end of operation).
Acetaminophen/Ibuprofen
A mixture of 1g acetaminophen and 300 mg ibuprofen (Maxigesic®IV) is administered during skin closure (end of operation)
Acetaminophen
1g acetaminophen is administered 6 hours after the first administration.
Acetaminophen/Ibuprofen
A mixture of 1g acetaminophen and 300 mg ibuprofen (Maxigesic®IV) is administered 6 hours after the first administration.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Gestational age \> 37+0 weeks
Exclusion Criteria
* Multiple pregnancy (e.g. twins, triplets)
* Body weight \< 50 kg
* Preeclampsia
* History of hypersensitivity to acetaminophen or ibuprofen
* History of upper gastrointestinal tract bleeding or gastric ulcer
* Underlying liver disease
* Underlying kidney disease or GFR \< 90 mL/min/1.73m2
* Heart failure or severe hypertension
* History of asthma
* Chronic use of barbital or tricyclic antidepressants
19 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jeong-Hwa Seo
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Junghwa Seo, MD, PhD
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2405-052-1535
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.